The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Open accessAbstract
The therapeutic application of ionizing radiation has been largely based on its cytocidal power combined with the ability to selectively target tumors. Radiotherapy effects on survival of cancer patients are generally interpreted as the consequence of improved local control of the tumor, directly decreasing systemic spread. Experimental data from multiple cancer models have provided sufficient evidence to propose a paradigm shift, whereby some of the effects of ionizing radiation are recognized as contributing to systemic antitumor immunity. Recent examples of objective responses achieved by adding radiotherapy to immunotherapy in metastatic cancer patients support this view. Therefore, the traditional palliative role of radiotherapy in metastatic disease is evolving into that of a powerful adjuvant for immunotherapy. This combination strategy adds to the current anticancer arsenal and offers opportunities to harness the immune system to extend survival, even among metastatic and heavily pretreated cancer patients. We briefly summarize key evidence supporting the role of radiotherapy as an immune adjuvant. A critical appraisal of the current status of knowledge must include potential immunosuppressive effects of radiation that can hamper its capacity to convert the irradiated tumor into an in situ, individualized vaccine. Moreover, we discuss some of the current challenges to translate this knowledge to the clinic as more trials testing radiation with different immunotherapies are proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“The confluence of proinflammatory cytokines produced by innate immune cells and danger signals generated by stressful death of the neoplastic cells activates tumor-specific T cells to perform antitumor activities (5).”
BackgroundSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“However, a modest increase in survival has been achieved in selected vaccinated cancer patients (69), which demonstrates some ability of the immune system to delay tumor progression (11).”
BackgroundCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Cited by
Radiomics: the bridge between medical imaging and personalized medicine
Lambin, P., Leijenaar, R. T. H., Deist, T. M., Peerlings, J., de Jong, E. E. C., van Timmeren, J., Sanduleanu, S., Larue, R. T. H. M., Even, A. J. G., Jochems, A., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.141 · Cited by 5,688
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,056
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
De Ruysscher, D., Niedermann, G., Burnet, N. G., Siva, S., Lee, A. W. M., & Hegi-Johnson, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0064-5 · Cited by 868
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 864
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
Self-citationAntigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Min, Y., Roche, K. C., Tian, S., Eblan, M. J., McKinnon, K. P., Caster, J. M., Chai, S., Herring, L. E., Zhang, L., Zhang, T., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.113 · Cited by 701
Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0115 · Cited by 688
Self-citationRadiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Golden, E. B., Chhabra, A., Chachoua, A., Adams, S., Donach, M., Fenton-Kerimian, M., Friedman, K., Ponzo, F., Babb, J. S., Goldberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00054-6 · Cited by 667
Self-citationSharabi, A. B., Nirschl, C. J., Kochel, C. M., Nirschl, T. R., Francica, B. J., Velarde, E., Deweese, T. L., & Drake, C. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0196 · Cited by 658
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Helen Barcellos-Hoff, M., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 624
Self-citationLu, K., He, C., Guo, N., Chan, C., Ni, K., Lan, G., Tang, H., Pelizzari, C., Fu, Y.-X., Spiotto, M. T., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0203-4 · Cited by 596
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy
Jarosz-Biej, M., Smolarczyk, R., Cichoń, T., & Kułach, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133212 · Cited by 546
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Self-citationFilatenkov, A., Baker, J., Mueller, A. M. S., Kenkel, J., Ahn, G.-O., Dutt, S., Zhang, N., Kohrt, H., Jensen, K., Dejbakhsh-Jones, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2824 · Cited by 474
Radiotherapy and Immunogenic Cell Death
Golden, E. B., & Apetoh, L. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.005 · Cited by 463
Fokas, E., Liersch, T., Fietkau, R., Hohenberger, W., Beissbarth, T., Hess, C., Becker, H., Ghadimi, M., Mrak, K., Merkel, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3769 · Cited by 454
Charged particle therapy—optimization, challenges and future directions
Loeffler, J. S., & Durante, M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.79 · Cited by 426
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Neutrophil‐Based Drug Delivery Systems
Chu, D., Dong, X., Shi, X., Zhang, C., & Wang, Z. (2018) · Advanced Materials · doi:10.1002/adma.201706245 · Cited by 386
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Filley, A. C., Henriquez, M., & Dey, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21586 · Cited by 386
Current Landscape of Immunotherapy in Breast Cancer: A Review
Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384
Combination immunotherapy: a road map
Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0218-5 · Cited by 374
Tang, C., Liao, Z., Gomez, D., Levy, L., Zhuang, Y., Gebremichael, R. A., Hong, D. S., Komaki, R., & Welsh, J. W. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.025 · Cited by 372
Current clinical trials testing the combination of immunotherapy with radiotherapy
Kang, J., Demaria, S., & Formenti, S. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0156-7 · Cited by 371
Self-citationRadiotherapy: Changing the Game in Immunotherapy
Demaria, S., Coleman, C. N., & Formenti, S. C. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.002 · Cited by 363
Self-citationSpatial Heterogeneity in the Tumor Microenvironment
Yuan, Y. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026583 · Cited by 342
Ni, K., Lan, G., Chan, C., Quigley, B., Lu, K., Aung, T., Guo, N., La Riviere, P., Weichselbaum, R. R., & Lin, W. (2018) · Nature Communications · doi:10.1038/s41467-018-04703-w · Cited by 336
Ma, W., Gilligan, B. M., Yuan, J., & Li, T. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0277-y · Cited by 327
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Tang, C., Wang, X., Soh, H., Seyedin, S., Cortez, M. A., Krishnan, S., Massarelli, E., Hong, D., Naing, A., Diab, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0069 · Cited by 322
The biology and treatment of oligometastatic cancer
Reyes, D. K., & Pienta, K. J. (2015) · Oncotarget · doi:10.18632/oncotarget.3455 · Cited by 320
Emerging Opportunities and Challenges in Cancer Immunotherapy
Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., & Melero, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0049 · Cited by 317
Self-citationBalermpas, P., Michel, Y., Wagenblast, J., Seitz, O., Weiss, C., Rödel, F., Rödel, C., & Fokas, E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.640 · Cited by 309
Yu, W.-D., Sun, G., Li, J., Xu, J., & Wang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.048 · Cited by 308
Demaria, S., Guha, C., Schoenfeld, J., Morris, Z., Monjazeb, A., Sikora, A., Crittenden, M., Shiao, S., Khleif, S., Gupta, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002038 · Cited by 301
Self-citationSafety of combining radiotherapy with immune-checkpoint inhibition
Hwang, W. L., Pike, L. R. G., Royce, T. J., Mahal, B. A., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 295
A snapshot of the PD-1/PD-L1 pathway
Ghosh, C., Luong, G., & Sun, Y. (2021) · Journal of Cancer · doi:10.7150/jca.57334 · Cited by 292
Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses
Chen, Q., Chen, M., & Liu, Z. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00271e · Cited by 288
Portrait of inflammatory response to ionizing radiation treatment
Di Maggio, F. M., Minafra, L., Forte, G. I., Cammarata, F. P., Lio, D., Messa, C., Gilardi, M. C., & Bravatà, V. (2015) · Journal of Inflammation · doi:10.1186/s12950-015-0058-3 · Cited by 286
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv209 · Cited by 280
Whole Tumor Antigen Vaccines: Where Are We?
Chiang, C., Coukos, G., & Kandalaft, L. (2015) · Vaccines · doi:10.3390/vaccines3020344 · Cited by 269
Lo Nigro, C., Macagno, M., Sangiolo, D., Bertolaccini, L., Aglietta, M., & Merlano, M. C. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.42 · Cited by 268
Tinganelli, W., & Durante, M. (2020) · Cancers · doi:10.3390/cancers12103022 · Cited by 267
Immunomodulation by radiotherapy in tumour control and normal tissue toxicity
Cytlak, U. M., Dyer, D. P., Honeychurch, J., Williams, K. J., Travis, M. A., & Illidge, T. M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00568-1 · Cited by 258
The dawn of vaccines for cancer prevention
Finn, O. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.140 · Cited by 254
TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy
Shiao, S. L., Ruffell, B., DeNardo, D. G., Faddegon, B. A., Park, C. C., & Coussens, L. M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0232 · Cited by 253
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P., & Špíšek, R. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968434 · Cited by 200
“As RT improves the clinical outcome of other treatment modalities such as surgery and chemotherapy, it is likely to enhance antitumor effect of various immunotherapeutic agents such as monoclonal antibodies, whole-cell or DC-based vaccines or TLR agonists.(54,68,69) For example, a case of the abscopal effect in patien…”
BackgroundGuo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168
“It remains unknown and is imperative to investigate whether restricted p53 activation in the TME promotes sustained tumor-specific T cell activation It is increasingly appreciated that activation of antitumor immunity is indispensable for the clinical benefits of radiotherapy and some types of chemotherapy (17-19).”
BackgroundExercise as adjunct therapy in cancer
Ashcraft, K. A., Warner, A. B., Jones, L. W., & Dewhirst, M. W. (2019) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2018.10.001 · Cited by 148
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients
van Meir, H., Nout, R. A., Welters, M. J. P., Loof, N. M., de Kam, M. L., van Ham, J. J., Samuels, S., Kenter, G. G., Cohen, A. F., Melief, C. J. M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1267095 · Cited by 143
The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy
Cogdill, A. P., Gaudreau, P. O., Arora, R., Gopalakrishnan, V., & Wargo, J. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.007 · Cited by 98
Irradiation and immunotherapy: From concept to the clinic
Salama, A. K. S., Postow, M. A., & Salama, J. K. (2016) · Cancer · doi:10.1002/cncr.29889 · Cited by 85
Pembrolizumab for advanced cervical cancer: Safety and efficacy
De Felice, F., Giudice, E., Bolomini, G., Distefano, M. G., Scambia, G., Fagotti, A., & Marchetti, C. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1850279 · Cited by 30
Metadata
- Authors
- Formenti, S. C., & Demaria, S.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-04
- Volume
- 105
- Issue
- 4
- Pages
- 256-265
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2140828776
- Cited by
- 1,053
- References
- 117
- FWCI
- 43.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.